Establishment Labs (NASDAQ:ESTA) Shares Up 5%

Establishment Labs Holdings Inc. (NASDAQ:ESTA)’s stock price was up 5% during mid-day trading on Tuesday . The stock traded as high as $50.49 and last traded at $50.14. Approximately 119,145 shares changed hands during mid-day trading, a decline of 74% from the average daily volume of 455,456 shares. The stock had previously closed at $47.76.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the company. Stephens reissued an “overweight” rating and set a $47.00 price target on shares of Establishment Labs in a report on Thursday, January 11th. JPMorgan Chase & Co. raised their price target on Establishment Labs from $46.00 to $53.00 and gave the company an “overweight” rating in a report on Thursday, February 29th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $64.00.

Establishment Labs Price Performance

The stock has a market capitalization of $1.38 billion, a price-to-earnings ratio of -16.74 and a beta of 1.23. The company has a current ratio of 3.06, a quick ratio of 1.67 and a debt-to-equity ratio of 10.26. The stock has a 50-day simple moving average of $42.45 and a 200 day simple moving average of $36.14.

Establishment Labs (NASDAQ:ESTA) last posted its quarterly earnings results on Wednesday, February 28th. The company reported ($0.79) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.95) by $0.16. Establishment Labs had a negative return on equity of 357.81% and a negative net margin of 47.53%. The company had revenue of $31.60 million during the quarter, compared to the consensus estimate of $31.44 million. During the same period last year, the business earned ($0.55) EPS. The business’s quarterly revenue was down 27.9% on a year-over-year basis. On average, equities research analysts forecast that Establishment Labs Holdings Inc. will post -1.58 EPS for the current fiscal year.

Hedge Funds Weigh In On Establishment Labs

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Legal & General Group Plc increased its holdings in Establishment Labs by 2.3% in the 4th quarter. Legal & General Group Plc now owns 6,965 shares of the company’s stock valued at $457,000 after buying an additional 157 shares during the period. Geode Capital Management LLC raised its stake in Establishment Labs by 0.8% during the first quarter. Geode Capital Management LLC now owns 22,736 shares of the company’s stock worth $1,540,000 after acquiring an additional 176 shares in the last quarter. California State Teachers Retirement System boosted its stake in shares of Establishment Labs by 1.3% in the 1st quarter. California State Teachers Retirement System now owns 16,285 shares of the company’s stock valued at $1,097,000 after purchasing an additional 204 shares in the last quarter. Walleye Capital LLC increased its position in shares of Establishment Labs by 3.9% during the 1st quarter. Walleye Capital LLC now owns 6,119 shares of the company’s stock worth $412,000 after purchasing an additional 228 shares in the last quarter. Finally, BNP Paribas Arbitrage SA boosted its position in Establishment Labs by 39.9% in the second quarter. BNP Paribas Arbitrage SA now owns 842 shares of the company’s stock valued at $46,000 after buying an additional 240 shares in the last quarter. Institutional investors own 72.91% of the company’s stock.

About Establishment Labs

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.